NCT00002362暂停3 期
A Randomized, Open-Label Superiority Trial Comparing Emtricitabine to Abacavir Within a Triple Drug Combination in Antiretroviral-Drug Naive HIV-1 Infected Patients
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 暂停
- 试验地点
- 20
研究概览
简要总结
This study will look at whether emtricitabine is as safe and effective as abacavir (ABC) when taken with stavudine (d4T) and efavirenz (EFV) in patients who have never taken anti-HIV drugs.
详细描述
Patients are randomized to receive open-label emtricitabine or ABC in combination with stavudine and efavirenz. Viral load and CD4+ cell counts are compared at Weeks 24 and 48. Patients are followed for 48 weeks.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •You may be eligible if you:
- •Are HIV-positive and generally healthy.
- •Have a viral load of 5,000 copies/ml or more.
- •Have CD4 cell counts of 200 cells/mm3 or more.
- •Are age 18 or older.
- •Agree to practice sexual abstinence or use effective barrier methods of birth control (such as condoms).
排除标准
- •You will not be eligible if you:
- •Have ever taken anti-HIV drugs for 3 days or more.
- •Have had certain AIDS-related infections.
- •Have had severe diarrhea within the past 30 days.
- •Are unable to eat at least 1 meal a day due to nausea, vomiting, or stomach pain.
- •Are being treated for active tuberculosis (TB).
- •Are pregnant or breast-feeding.
- •Use illegal drugs or alcohol that make it difficult for you to take study drugs or keep clinic appointments.
- •Are taking certain medications, or have certain other conditions or diseases (see the technical summary for more detail).
研究者
研究点 (20)
Loading locations...
相似试验
Unknown
3 期
A Comparison of Emtricitabine and Stavudine Used With Didanosine Plus Efavirenz in HIV-Infected Patients Who Have Not Taken Anti-HIV DrugsHIV InfectionsNCT00006208Triangle Pharmaceuticals
撤回
不适用
Same-Day Treatment With Genvoya vs. EFV/TDF/3TCHIV/AIDSNCT03405194Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic
已完成
2 期
Combination Antiretroviral Therapy (cART) for PBCPrimary Biliary CholangitisNCT03954327University of Alberta37
已完成
3 期
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected PatientsAcquired Immunodeficiency SyndromeHIV InfectionsNCT01475838Gilead Sciences438
已完成
2 期
A Study of Abacavir Plus Indinavir Sulfate Plus Efavirenz in HIV-Infected PatientsHIV InfectionsNCT00001086National Institute of Allergy and Infectious Diseases (NIAID)300